Sanofi Cholesterol Drug Gets FDA Advisers’ Partial Backing

Updated on

Sanofi and Regeneron Pharmaceuticals Inc. won the backing of U.S. regulatory advisers for their powerful cholesterol-lowering drug Praluent, moving it one step closer to approval for sale this summer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.